2. Academic Validation
  3. Pan cancer research reveals the role of PTGDS in tumor suppression and immune regulation

Pan cancer research reveals the role of PTGDS in tumor suppression and immune regulation

  • NPJ Precis Oncol. 2025 Sep 30;9(1):319. doi: 10.1038/s41698-025-01097-z.
Jiajin Li # 1 2,  Zheng Qu # 1,  Dacheng Zhu # 2,  Ye Lu # 1,  Jiaxin Lu 1,  Zhen Wu 2,  Luxiao Zhang 1,  Pengpeng Zhang 3,  Yiqin Xia 4,  Shengbin Pei 5 6
Affiliations

Affiliations

  • 1 Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • 2 The Second Clinical School of Medicine, Anhui Medical University, Hefei, China.
  • 3 Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. zpp19940120@tmu.edu.cn.
  • 4 Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 15895826258@163.com.
  • 5 Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. b2023003105@pumc.edu.cn.
  • 6 Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. b2023003105@pumc.edu.cn.
  • # Contributed equally.
PMID: 41028158 DOI: 10.1038/s41698-025-01097-z
Abstract

Prostaglandin D2 synthase (PTGDS), a newly identified anti-tumor target, shows promise in inhibiting various cancers and plays significant roles in the tumor microenvironment and immune regulation, yet a comprehensive pan-cancer analysis of its expression and prognostic value remains lacking. This study used multi-omics data from public databases to assess PTGDS's expression, mutation, and modification in multiple cancers, integrated single-cell and spatial transcriptomic data to explore its relationship with immune cells, and conducted in vitro and in vivo experiments in breast Cancer (BRCA). Results showed that PTGDS is significantly dysregulated in most cancers, with its expression associated with different outcomes depending on Cancer type. It correlates with epigenetic and biological functions, and low expression in BRCA indicates poor prognosis. Overexpression of PTGDS can inhibit breast Cancer cell proliferation and invasion, increase CD8+ T - cell activity, and enhance anti-tumor immunity. Combining it with anti-PD-L1 improves BRCA treatment. PTGDS is a potential prognostic biomarker and a novel immunotherapy target for BRCA.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z